Article
Therapeutic strategies for congenital myasthenic syndromes.
Annals of the New York Academy of Sciences - 1 Jan 2018
Lee Manon, Beeson David, Palace Jacqueline
Abstract excerpt
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS. The present-day drug repertoire comprises acetylcholinesterase inhibitors (mainly pyridostigmine),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
